| scholarly article | Q13442814 |
| P50 | author | Philip Van Damme | Q32426029 |
| Ludo Van Den Bosch | Q32426032 | ||
| Robin Lemmens | Q47502949 | ||
| Laura Rué | Q62946398 | ||
| Bart Roucourt | Q114573426 | ||
| P2093 | author name string | Peter Weber | |
| Bart De Strooper | |||
| Lucía Chávez-Gutiérrez | |||
| Maarten Dewilde | |||
| Wim Robberecht | |||
| Susan Little | |||
| Gholamreza Hassanzadeh-Ghassabeh | |||
| Jurgen Haustraete | |||
| Adam Curnock | |||
| Lies Schoonaert | |||
| Mieke Timmers | |||
| Peter Joyce | |||
| P2860 | cites work | Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS | Q21144409 |
| Structure of a nanobody-stabilized active state of the β(2) adrenoceptor | Q24597139 | ||
| Eph/ephrin molecules--a hub for signaling and endocytosis | Q24611588 | ||
| Properties, production, and applications of camelid single-domain antibody fragments | Q24676749 | ||
| Blood-CNS Barrier Impairment in ALS patients versus an animal model | Q27026792 | ||
| Structural Plasticity of Eph Receptor A4 Facilitates Cross-Class Ephrin Signaling | Q27657815 | ||
| Structural Characterization of the EphA4-Ephrin-B2 Complex Reveals New Features Enabling Eph-Ephrin Binding Promiscuity | Q27658020 | ||
| Insights into Eph receptor tyrosine kinase activation from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5 | Q27679723 | ||
| Nanobody stabilization of G protein-coupled receptor conformational states. | Q27690729 | ||
| Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling | Q28258431 | ||
| Naturally occurring antibodies devoid of light chains | Q28269589 | ||
| Nanobodies: natural single-domain antibodies | Q28287268 | ||
| Single-domain antibodies as building blocks for novel therapeutics | Q28290310 | ||
| Ephrin-B3 is the midline barrier that prevents corticospinal tract axons from recrossing, allowing for unilateral motor control | Q28362268 | ||
| Inhibition of EphA7 up-regulation after spinal cord injury reduces apoptosis and promotes locomotor recovery | Q28578350 | ||
| Regeneration-enhancing effects of EphA4 blocking peptide following corticospinal tract injury in adult rat spinal cord | Q28584025 | ||
| Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice | Q28592877 | ||
| Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors | Q28647596 | ||
| EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-β oligomers | Q29347252 | ||
| Eph-ephrin bidirectional signaling in physiology and disease | Q29617975 | ||
| Oligodendrocytes: biology and pathology | Q30051584 | ||
| Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen | Q31117894 | ||
| Discovery and characterization of a novel cyclic peptide that effectively inhibits ephrin binding to the EphA4 receptor and displays anti-angiogenesis activity | Q31144324 | ||
| Isolation and affinity maturation of hapten-specific antibodies | Q33279884 | ||
| Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth | Q33897550 | ||
| Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease | Q33919522 | ||
| Crystal structure of the ligand-binding domain of the promiscuous EphA4 receptor reveals two distinct conformations | Q34170551 | ||
| HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery | Q34564346 | ||
| The growth cone cytoskeleton in axon outgrowth and guidance. | Q34577996 | ||
| PEGylated antibodies and antibody fragments for improved therapy: a review | Q34674773 | ||
| An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke. | Q34688738 | ||
| Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor | Q34756811 | ||
| Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. | Q35080243 | ||
| A novel platform for engineering blood-brain barrier-crossing bispecific biologics | Q35214538 | ||
| Myelin-derived ephrinB3 restricts axonal regeneration and recovery after adult CNS injury. | Q35882318 | ||
| A role for ephrin-A5 in axonal sprouting, recovery, and activity-dependent plasticity after stroke | Q36170813 | ||
| Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor | Q36296187 | ||
| Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination | Q36465147 | ||
| Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier | Q36637219 | ||
| Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor | Q36914295 | ||
| Eph receptor signaling and ephrins | Q37122330 | ||
| The impact of PEGylation on biological therapies | Q37263179 | ||
| Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond | Q37642283 | ||
| Dancing with the dead: Eph receptors and their kinase-null partners | Q37860149 | ||
| Targeting Eph receptors with peptides and small molecules: progress and challenges | Q37951723 | ||
| Receptor-mediated endocytosis and brain delivery of therapeutic biologics | Q38120524 | ||
| Therapeutic perspectives of Eph-ephrin system modulation. | Q38167588 | ||
| Therapeutic targeting of EPH receptors and their ligands | Q38174793 | ||
| Nanobody-based products as research and diagnostic tools | Q38201856 | ||
| EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans | Q38322311 | ||
| Mechanisms of ephrin-Eph signalling in development, physiology and disease. | Q38704281 | ||
| Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging | Q39325717 | ||
| Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents | Q40390422 | ||
| Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability | Q41063994 | ||
| Axo-Glia Interaction Preceding CNS Myelination Is Regulated by Bidirectional Eph-Ephrin Signaling | Q41836900 | ||
| Improved axonal regeneration after spinal cord injury in mice with conditional deletion of ephrin B2 under the GFAP promoter. | Q41873819 | ||
| Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors | Q41875227 | ||
| Nanobodies as modulators of inflammation: potential applications for acute brain injury | Q42105969 | ||
| Immunolocalization of the receptor tyrosine kinase EphA4 in the adult rat central nervous system. | Q42448261 | ||
| Albumin binding as a general strategy for improving the pharmacokinetics of proteins | Q44209151 | ||
| Modifying expression of EphA4 and its downstream targets improves functional recovery after stroke | Q44310626 | ||
| Targeting the EphA4 receptor in the nervous system with biologically active peptides | Q44707568 | ||
| Sizes of interface residues account for cross-class binding affinity patterns in Eph receptor-ephrin families | Q46150489 | ||
| Control of axonophilic migration of oligodendrocyte precursor cells by Eph-ephrin interaction. | Q46478400 | ||
| Regulation of EphA 4 kinase activity is required for a subset of axon guidance decisions suggesting a key role for receptor clustering in Eph function | Q46652050 | ||
| The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells | Q46791405 | ||
| Ephrin-B2 and EphB2 regulation of astrocyte-meningeal fibroblast interactions in response to spinal cord lesions in adult rats. | Q47659849 | ||
| Localization of EphA4 in axon terminals and dendritic spines of adult rat hippocampus | Q48273270 | ||
| Accumulation of the inhibitory receptor EphA4 may prevent regeneration of corticospinal tract axons following lesion | Q48579237 | ||
| Expression and activation of EphA4 in the human brain after traumatic injury. | Q48668285 | ||
| Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis | Q49082819 | ||
| Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs | Q73128251 | ||
| Half-lives of homologous serum albumins in several species | Q73190627 | ||
| Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis | Q83452226 | ||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 11452-11465 | |
| P577 | publication date | 2017-05-19 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Identification and characterization of Nanobodies targeting the EphA4 receptor | |
| P478 | volume | 292 |
| Q83227810 | A toolbox of nanobodies developed and validated for use as intrabodies and nanoscale immunolabels in mammalian brain neurons |
| Q60933281 | EphA4-ADAM10 Interplay Patterns the Cochlear Sensory Epithelium through Local Disruption of Adherens Junctions |
| Q98466240 | Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics |
| Q101335200 | Recombinant Antibodies in Basic Neuroscience Research |
| Q90613923 | The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications |
Search more.